Navigation Links
Quick, easy test identifies aggressive type of lung cancer in never-smokers
Date:2/25/2011

An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found.

Dr Ping Yang from the Mayo Clinic, Rochester, USA, and colleagues, reported the findings at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 24-26 February 2011, Lugano, Switzerland.

Approximately 8% - 12% of patients with lung adenocarcinoma who have never smoked cigarettes carry tumors that express a protein product called anaplastic lymphoma kinase (ALK), Dr Yang said. "This subset of patients are at more than double the risk of experiencing disease progression or recurrence within 5 years of initial diagnosis compared to never-smokers whose lung adenocarcinoma tumors are ALK-negative."

The ability to test for ALK status in these patients may help doctors select the most appropriate therapies for maximum clinical benefit, Dr Yang explained. Her group's study aimed to see whether immunohistochemistry screening, followed by a confirmatory test using fluorescence in situ hybridization (FISH), is a practical way to do this.

Immunohistochemistry tests use antibodies to identify specific proteins in tissue sections; FISH uses fluorescent probes to bind to specific DNA sequences in the chromosomes of individual cells.

In a study of 303 samples, the research team found that immunohistochemistry results correlated well with the results of FISH. Tissue samples with the highest immunohistochemistry scores (IHC 3+) were all FISH positive, while those with no immunohistochemistry staining (IHC 0) were FISH negative.

Based on these findings, only samples that were scored with the intermediate IHC scores of 1+ and 2+ would need confirmatory testing with FISH, Dr Yang explained. "In this particular cohort, IHC score 2+ and 1+ cases represented approximately 27% of those screened. Even if confirmatory testing is done on all IHC 2+ and 1+ cases, confirmatory testing could be avoided on roughly three quarters of the cases."

Immunohistochemistry is routinely performed in pathology labs and is a relatively inexpensive and rapid test method. "Because it is already performed in most pathology labs, testing can be done on-site versus sending a sample to another diagnostic testing site. Thus, IHC may be a good initial screening tool for ALK status," Dr Yang explained.

Overall, the researchers found that 8.2-12.2% of this never-smoking group with lung adenocarcinoma had tumors that expressed ALK. The ALK positive tumors were significantly more aggressive as measured by tumor grade of differentiation and stage, and were diagnosed in younger patients, Dr Yang said. However, there are no guidelines or standard protocols for ALK testing by IHC at the present time; proper standardization and validation of IHC procedures for ALK testing are needed, including evaluating the effectiveness of different antibodies, Dr. Yang added.

Commenting on the research, which she was not involved in, Dr Fiona Blackhall, Consultant Medical Oncologist and Honorary Senior Lecturer at The Christie Hospital NHS Foundation Trust, and Manchester Cancer Research Centre, UK said: "Dr Yang and colleagues have conducted an important study showing that immunohistochemistry may be an efficient screen to identify cases for confirmatory FISH. Their work provides a basis from which to evolve a practical, clinical testing algorithm that incorporates IHC as a first step."

"Further work is now needed to validate these findings, optimize the methodology for IHC and the criteria for FISH," Dr Blackhall added. "Their finding that patients with ALK-positive tumors may have a worse outcome following surgery is provocative, highlighting the clinical and therapeutic importance of identifying and learning more about this molecular subtype of non-small cell lung cancer."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Pitt-led researchers create quick, simple fluorescent detector for TB
2. Needle-in-a-haystack search identifies potential brain disease drug
3. UCSF study identifies chemicals in pregnant women
4. Study identifies new genetic signatures of breast cancer drug resistance
5. Research identifies drug target for prion diseases, mad cow
6. Large-scale analysis identifies new genetic alterations associated with height
7. Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution
8. Transcription factor scan identifies genetic cause for inherited blindness
9. Motor Neurone Disease Association study identifies MND biomarker
10. New research identifies the plight of farmland birds
11. Study identifies key molecules in multiple myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... , Nov. 29, 2016   ... identification and object recognition technologies, today released ... for fingerprint recognition solutions that run on ... fingerprint template using less than 128KB of ... compact devices that have limited on-board resources, ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory ... experience and security for consumer electronics, and ... financial and retail industry, today announced a global ... convenient way to authenticate users of mobile banking ... TrulySecure™ software which requires no specialized ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... -- AskLinkerReports.com has published a report on Amyloglucosidase ... 2016 Market Research Report. From a basic outline of the ... all covered in the report. This report projects investment feasibility ... the Amyloglucosidase industry. ... , Complete report ...
(Date:12/8/2016)... DIEGO , Dec. 8, 2016  Renova™ ... for congestive heart failure and type 2 diabetes, ... for a novel adeno-associated virus (AAV) vector developed ... , M.D., Ph.D., at Stanford University. The company ... its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ability ... optogenetics — is key to exciting advances in the study and mapping of ... projected via free-space optics stimulates small, transparent organisms and excites neurons within superficial ...
(Date:12/8/2016)... , December 8, 2016 ... für Molekulargenetik, erweitert seine Palette an anpassbaren SureSeq™ ... Custom FH Panels, das ein schnelles und kostengünstiges ... Das Panel bietet eine Erkennung von Einzel-Nukleotid-Variationen (Single ... mit einem einzigen kleinen Panel und ermöglicht eine ...
Breaking Biology Technology: